Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system
Authors:
- 8 February 2016
- journal article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 19 (6) , 568-575
Abstract
Objectives: Identify how many RA patients newly initiated on bDMARD therapy switch to another bDMARD during the first year of treatment; evaluate the factors and reasons associated with bDMARD switching; and compare the RA related healthcare resource utilization (HCRU) and costs between switchers versus non-switchers during the post-index period.Methods: A retrospective cohort study was conducted in RA patients using the Kaiser Permanente Southern California (KPSC) database with the study time period of 1-Jan-2007 to 31-Dec-2012. The index date was defined as the date of the first bDMARD prescription. Patients had to have continuous membership eligibility with drug benefit and no prior history of bDMARD during the 24 months prior index date. bDMARD switching was defined as a different bDMARD claim during post index. A multivariable logistic regression model was used to evaluate factors associated with switchers versus non-switchers. Chart notes were reviewed to evaluate reasons for switching from ...Keywords
This publication has 16 references indexed in Scilit:
- Sociodemographic Characteristics of Members of a Large, Integrated Health Care System: Comparison with US Census Bureau DataThe Permanente Journal, 2012
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Factors Associated With the Initiation of Disease-Modifying Antirheumatic Drugs in Newly Diagnosed Rheumatoid Arthritis: A Retrospective Claims Database StudyClinical Therapeutics, 2012
- Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohortArthritis Care & Research, 2011
- Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskeletal Disorders, 2011
- Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001–2005Arthritis Care & Research, 2010
- American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritisArthritis Care & Research, 2008
- Switching between anti-tumour necrosis factors: trying to get a handle on a complex issueAnnals of the Rheumatic Diseases, 2007
- The burden of musculoskeletal disease—a global perspectiveClinical Rheumatology, 2006
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005